82952-64-5

Basic information

• Product Name: Trimetrexate glucuronate
• Synonyms: CI 898 TRIHYDROCHLORIDE;5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]quinazoline-2,4-diamine D-glucuronate;Trimetrexate glucuronate;5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediaminetrihydrochloride;CI 898 dihydrochloride
• CAS NO: 82952-64-5
• Molecular Formula: C25H33N5O10
• Molecular Weight: 563.56
• Mol File: 82952-64-5.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 647 °C at 760 mmHg
• Flash Point: 345.1 °C
• Appearance: /
• Density: 1.305 g/cm³
• Vapor Pressure: 1.26E-16mmHg at 25°C
• Storage Temp.: Store at -20°C
• CAS DataBase Reference: Trimetrexate glucuronate(CAS DataBase Reference)
• NIST Chemistry Reference: Trimetrexate glucuronate(82952-64-5)
• EPA Substance Registry System: Trimetrexate glucuronate(82952-64-5)

Safety Data

• Hazardous Substances Data: 82952-64-5(Hazardous Substances Data)

Usage

Description

Trimetrexate glucuronate is a nonclassical antifolate introduced in the U.S.A. and Canada as second-line therapy for the treatment of Pneumocystis carinii pneumonia (PCP) and toxoplasmosis in AIDS patients who are refractory or intolerant to co-trimoxazole therapy. Trimetrexate glucuronate is reportedly to be in clinical trials for the treatment of several types of cancer including colorectal, gastric, pancreas, prostate, bladder, lung, breast, head, and neck cancers. It is also in early clinical trials for topical use in treating psoriasis and as an oral drug to treat rheumatoid arthritis. The mechanism of action of trimetrexate glucuronate is via inhibition of the enzyme dihydrofolate reductase which mediates the reduction of dihydrofolate to tetrahydrofolic acid and results in disruption of DNA, RNA and protein synthesis, with consequent cell death. Due to its toxicity to bone marrow and the GI tract, trimetrexate glucuronate must be concurrently administered with leucovorin as a rescue agent.

Uses

Different sources of media describe the Uses of 82952-64-5 differently. You can refer to the following data:
1. Antineoplastic.
2. CI 898 Glucuronate is a dihydrofolate reductase (DHFR) inhibitor.

Manufacturing Process

A mixture of 2,4-diamino-5-methyl-6-[(3,4,5- trimethoxyanilino)methyl]quinazoline (1.0 g) and glucuronic acid (0.7 g) in methanol (65 ml) is heated to dissolve the solid. The solution is cooled to 10°C and filtered to remove a small amount of solid. The filtrate is heated to reflux and ethyl acetate is added to the cloud point. The warm solution is filtered then slowly cooled. The solid that forms is collected, washed first with ethylacetate, then with ether and dried in vacuo at 60°C to give the 4- diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline D_x0002_glucuronate as a yellow powder with no definite melting point.

Brand name

Neutrexin (MedImmune).

Therapeutic Function

Antineoplastic

Biological Activity

Potent lipophilic inhibitor of dihydrofolate reductase (DHFR) that displays antineoplastic and antiprotozoal properties. Inhibits protozoal, bacterial and human DHFR with IC 50 values of 1.4, 6.1 and 3.2 nM respectively. Affects G 1 /S phase cell cycle progression.

InChI:InChI=1/C19H23N5O3.C6H10O7/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3;7-1-2(8)3(9)4(10)5(11)6(12)13/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24);1-5,8-11H,(H,12,13)/t;2-,3+,4-,5-/m.0/s1

Relevant articles and documents

2-4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline salts

2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline salts, pharmaceutical compositions containing said salts, methods of treating malaria, and bacterial infections employing said salts and compositions and methods for producing said salts.